STAT-Dx Seals CE-IVD Mark For POC Syndromic Testing System
Executive Summary
STAT-Dx has sealed a CE-IVD mark for its point-of-care syndromic testing system and a respiratory panel. The firm will launch the system in Europe in the second half of 2018.
You may also be interested in...
Qiagen Buys STAT-Dx To Launch Next-Gen Syndromic Testing System
Qiagen has agreed to acquire STAT-Dx, a start-up that developed a multiplex diagnostic for common syndromes, for about $147m in upfront cash, and up to $44m in regulatory and commercial milestones.
STAT-DX Aims To Take On Rival BioFire In Syndromic Testing
Barcelona start-up STAT-DX is gearing up to launch a new decentralized multiplex PCR system in the rapidly growing field of syndromic testing. The company, which will face larger rivals such as bioMérieux's BioFire, will unveil its new point-of-care platform at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), in Vienna from 22-25 April.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.